1. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
   Tom Van Maerken et al, 2014, Cancer Letters CrossRef
2. Effect of low doses of actinomycin D on neuroblastoma cell lines
   Constanza L. Cortes et al, 2016, Mol Cancer CrossRef
3. The MYCN Protein in Health and Disease
   María Victoria Ruiz-Pérez et al, 2017, Genes CrossRef
4. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma
   Daniela Raguer Valadão de Souza et al, 2011, Pediatr. Blood Cancer CrossRef
5. Well-Differentiated/Dedifferentiated Liposarcomas
   Sachiv Sheth et al, 2012, Pathology Case Reviews CrossRef
6. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation
   Tongsen Zheng et al, 2010, Tumor Biol. CrossRef
7. Combination therapy with p53–MDM2 binding inhibitors for malignancies
   Zegao Jin et al, 2015, Med Chem Res CrossRef
8. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma
   John M. Yavorski et al, 2016, Cell Cycle CrossRef
9. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
   Alan Van Goethem et al, 2017, Oncotarget CrossRef
10. MYCN in Neuroblastoma: “Old Wine into New Wineskins”
    Maria Braoudaki et al, 2021, Diseases CrossRef
11. Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity
    Maja C. Stöber et al, 2024, Cell Reports CrossRef
12. The role of cell cycle-related genes in the tumorigenesis of adrenal and thyroid neuroendocrine tumors.
    Ekaterina Filipovich et al, 2024, Heliyon CrossRef